(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 24.2MM | +8% |
Operating Income | -41.3MM | -6% |
Operating Expenses | 65.5MM | - |
Net Income | -41.6MM | -6% |
R&D | 29.9MM | -11% |
G&A | 32.4MM | +6% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation observed in preclinical studies -- BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the first patients have bee
Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM), has sold 18,235 shares of the company on March 21, 2024, according to a recent SEC Filing.
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity, has reported an insider sell according to a recent SEC filing.
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity, has reported an insider sell according to a recent SEC filing.
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity, has reported an insider sell according to a recent SEC filing.
BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on March 6, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 13,780 shares of its common stock to three new employees, consisting of inducement stock options to purch
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Company will participate in two upcoming investor conferences. David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Barclays 26th Annual Global Healthcare Conference on Thursday, Marc
Rhythm Pharmaceuticals ( NASDAQ:RYTM ) Full Year 2023 Results Key Financial Results Revenue: US$77.4m (up 228% from FY...
Shareholders might have noticed that Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) filed its yearly result this time...
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2023 Earnings Call Transcript February 22, 2024 Rhythm Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.7 EPS, expectations were $-0.7. Rhythm Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies […]